Search - tctmd.com

Displaying 81 - 100 of 142

Sort: Relevancy | Date

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Daily News

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

Michael O'Riordan

January 28, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

标准胸部 CT：是难得的 CAD 检测良机，但需要新指南和新态度支持

L.A. McKeown

January 19, 2016

News Daily News

Standard Chest CT: A Missed Opportunity for CAD Detection Warranting New Guidelines and Attitudes

L.A. McKeown

January 19, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

BP Lowering Reduces Vascular Risk Regardless of Baseline BP and Disease History

Michael O'Riordan

December 27, 2015

News Daily News

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Shelley Wood

December 16, 2015

News Daily News

More Than Half of CVD Studies Exclude Patients With Kidney Disease

Michael O'Riordan

December 03, 2015

Presentation

Representation of Patients With Kidney Disease in Trials of CVD Interventions

Presenter: Ioannis Konstantinidis

December 02, 2015

News Daily News

FDA: Long-Term Clopidogrel Neither Ups, Nor Cuts Risk of Death in CVD Patients

Yael L. Maxwell

November 08, 2015

News Daily News

FDA: Long-Term Clopidogrel Neither Ups, Nor Cuts Risk of Death in CVD Patients

Yael L. Maxwell

November 08, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

News Daily News

NEJM支持 Robert Califf担任FDA局长

L.A. McKeown

October 30, 2015

News Daily News

NEJM Endorses Robert Califf for FDA Commissioner

L.A. McKeown

October 30, 2015

News Daily News

NEJM Apoya a Robert Califf como Comisionado de la FDA

L.A. McKeown

October 30, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

Advertisement

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

标准胸部 CT：是难得的 CAD 检测良机，但需要新指南和新态度支持

Standard Chest CT: A Missed Opportunity for CAD Detection Warranting New Guidelines and Attitudes

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

BP Lowering Reduces Vascular Risk Regardless of Baseline BP and Disease History

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

More Than Half of CVD Studies Exclude Patients With Kidney Disease

Representation of Patients With Kidney Disease in Trials of CVD Interventions

FDA: Long-Term Clopidogrel Neither Ups, Nor Cuts Risk of Death in CVD Patients

FDA: Long-Term Clopidogrel Neither Ups, Nor Cuts Risk of Death in CVD Patients

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

NEJM支持 Robert Califf担任FDA局长

NEJM Endorses Robert Califf for FDA Commissioner

NEJM Apoya a Robert Califf como Comisionado de la FDA

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content